Car­mot rais­es an­oth­er $150M for obe­si­ty drugs, though race by com­peti­tors is well un­der­way

Car­mot Ther­a­peu­tics an­nounced a $150 mil­lion Se­ries E round that it plans to use to fund sev­er­al tri­als of its obe­si­ty drugs.

Its lead can­di­date is a GLP-1/GIP dual re­cep­tor mod­u­la­tor head­ing in­to test­ing for obe­si­ty and di­a­betes. The lat­est round brings the start­up’s to­tal raised to around $370 mil­lion, ac­cord­ing to the com­pa­ny.

Sim­i­lar to Eli Lil­ly’s Moun­jaro, Car­mot’s lead drugs tar­get hor­mones that to­geth­er can im­pact in­sulin pro­duc­tion and ap­petite. Its lead com­pound is CT-388, a once-week­ly in­jec­tion it is tak­ing in­to Phase II. It al­so has a dai­ly in­jec­tion with the same mech­a­nism and an oral GLP-1; a Phase I tri­al is in the works.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN